Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dosing of Preoperative Gabapentin for PONV Prevention
NCT04622618Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gabapentin in postoperative nausea and vomiting (PONV) and postoperative pain (3 arms), sponsored by Ain Shams University. Primary endpoints: Incidence of postoperative nausea and vomiting episodes at 24 hours and Severity of nausea at 24 hours. Started Sep 2020; status: completed.
02
Drugs
gabapentin
03
Conditions
postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on NCT04622618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622618.